RESUMEN
Uncontrolled use of medicines bring with it serious health problems. Long-term and uncontrolled use of steroids, without the supervision of a healthcare professional, may cause unexpected infections due to immunosuppression. The authors present a patient with maxillary osteomyelitis caused by Kocuria species in a 41-year-old male who has been receiving methylprednisolone without control for 1.5 years.
Asunto(s)
Antiinflamatorios/efectos adversos , Huésped Inmunocomprometido , Metilprednisolona/efectos adversos , Micrococcaceae , Osteomielitis/microbiología , Automedicación/efectos adversos , Adulto , Humanos , Masculino , Maxilar , Osteomielitis/etiología , Factores de TiempoRESUMEN
The purpose of this study was to evaluate the sufficiency of the mandibular symphysis as a donor site for unilateral and bilateral alveolar grafting, measuring both the alveolar cleft volume and maximum bone graft volume that can be harvested from the mandibular symphysis using 3-dimensional computed tomography (CT) and software in children and adults. Computed tomography data obtained from 20 unilateral and bilateral cleft lip palates patients in the preoperative period were used in this study. The patients were divided into 2 groups: children (female, nâ=â5; male, nâ=â5) and adults (female, nâ=â5; male, nâ=â5). The required bone graft volume for grafting and the maximum bone graft volume that can be harvested from the mandibular symphysis were measured based on cone beam CT data and software. The average required bone graft volume (cleft volume) for unilateral alveolar grafting was 963.51â±â172.31âmm in the children and 1001.21â±â268.16âmm in the adults. The average required bone graft volume for bilateral alveolar grafting was 1457.82â±â148.18âmm in the children and 2189.59â±â600.97âmm in the adults. The average the mandibular symphysis bone graft volume was 819.29â±â330.85âmm in the children and 2164.9â±â1095.86âmm in the adults. The results demonstrated that the mandibular symphysis region provided an adequate bone volume for alveolar grafting in adults with unilateral alveolar clefts. However, it is difficult to standardize these results, due to cleft volume and graft volume that could be harvested from the mandibular symphysis are highly variable among individuals.
Asunto(s)
Injerto de Hueso Alveolar/métodos , Trasplante Óseo/métodos , Fisura del Paladar/cirugía , Mandíbula/cirugía , Recolección de Tejidos y Órganos/métodos , Adolescente , Adulto , Niño , Fisura del Paladar/diagnóstico por imagen , Tomografía Computarizada de Haz Cónico , Femenino , Humanos , Imagenología Tridimensional , Masculino , Adulto JovenRESUMEN
BACKGROUND: Collagen membranes have some benefits include promoting wound healing through isolation, clot stabilization, wound stability, and hemostasis, enhancing primary wound coverage through its chemotactic ability to attract fibroblasts, and augmenting flap thickness by providing a collagenous scaffold. The purpose of this study was to compare primary and secondary healing and collagen membrane-based primary healing after surgical removal of partial impacted mandibular third molars, evaluating the incidence of postoperative complications and analyzing the swelling, mouth opening, and pain. METHODS: This was a prospective, randomized controlled study. Patients were randomly assigned to three groups: the SC (Secondary closure) group, the PC (Primary closure) group, and the MBPC (membrane based primary closure) group. Data were collected on pain, mouth opening, swelling, and complications experienced by the patients. RESULTS: There was no statistically significant difference between the groups for the pain (p > 0.05), relatively. The swelling recorded on postoperative days 2 and 7 was lower in the SC group than in the PC (p = 0.046 and 0.00) and in MBPC (p = 0.005 and 0.002) groups, respectively. Mouth opening showed a statistically significant difference between the three groups at day 2 (p = 0.00). Wound dehiscence was shown in 6 patients in the PC (20%) group and 2 patients in the MBPC (6.7%) group. Dry socket was observed 3 patients in the SC group (10%), 2 patients in the PC group (6.7%), and no dry socket in the MBPC group. No cases of infection or postoperative bleeding were encountered. CONCLUSIONS: The secondary closure provides a marked advantage over the primary closure in terms of swelling and mouth opening. However, the absence of alveolitis in the primary closure using the collagen membrane and minimal wound dehiscence, suggests that membrane use may support primary healing in terms of wound healing.
Asunto(s)
Materiales Biocompatibles/administración & dosificación , Colágeno/administración & dosificación , Tercer Molar/cirugía , Complicaciones Posoperatorias/prevención & control , Extracción Dental/efectos adversos , Diente Impactado/cirugía , Técnicas de Cierre de Heridas , Edema/prevención & control , Femenino , Humanos , Masculino , Mandíbula/cirugía , Dolor Postoperatorio/prevención & control , Estudios Prospectivos , Trismo/prevención & control , Cicatrización de Heridas , Adulto JovenRESUMEN
PURPOSE: The effect of a single-dose of pre-emptive pregabalin is still unknown, although it is used as an adjuvant in controlling acute postoperative pain. The purpose of this study was to evaluate the effects of pre-emptive single-dose pregabalin on postoperative acute pain and 24-hour opioid consumption in patients who underwent double-jaw surgery. PATIENTS AND METHODS: Forty patients (18 to 45 yr old; American Society of Anesthesiologists status I to II) for whom elective double-jaw surgery was planned under general anesthesia were included in this study, which had been planned as a prospective, randomized, and double-blinded study. Patients were randomly divided into 2 groups: the pregabalin group (n = 20) was given pregabalin 150 mg orally 1 hour before general anesthesia and the placebo group (n = 20) was given an oral placebo capsule. The groups were administered the routine general anesthesia protocol. Postoperative analgesia was performed intravenously in the 2 groups twice a day with dexketoprofen trometamol 50 mg and patient-controlled analgesia with fentanyl. Postoperative analgesia was evaluated using the visual analog scale (VAS). Fentanyl consumption, additional analgesia requirement, and side-effects were recorded during the first 24 hours after surgery. Descriptive and bivariate statistics were computed, and significance was set at a P value less than .05. RESULTS: Compared with placebo, the VAS score was statistically lower in the pregabalin group during the early postoperative period (P < .05). The 24-hour opioid consumption was significantly higher in the placebo group compared with the pregabalin group (509.40 ± 261.56 vs. 260.10 ± 246.53 µq, respectively; P = .004). In addition, the analgesia requirement was statistically lower in the pregabalin group (P < .05). Nausea or vomiting was observed more often in the placebo group, whereas other side-effects were similar for the 2 groups. CONCLUSION: A single 150-mg dose of pre-emptive pregabalin decreased postoperative opioid consumption in the first 24 hours after double-jaw surgery. Multimodal analgesia techniques that contain pre-emptive analgesia can be used successfully in preventing postoperative pain caused by orthognathic surgery.
Asunto(s)
Analgésicos/uso terapéutico , Narcóticos/uso terapéutico , Procedimientos Quirúrgicos Ortognáticos/métodos , Dolor Postoperatorio/prevención & control , Pregabalina/uso terapéutico , Premedicación , Adolescente , Adulto , Analgesia Controlada por el Paciente/métodos , Analgésicos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Método Doble Ciego , Femenino , Fentanilo/administración & dosificación , Fentanilo/uso terapéutico , Estudios de Seguimiento , Humanos , Cetoprofeno/análogos & derivados , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana Edad , Narcóticos/administración & dosificación , Osteotomía Le Fort/métodos , Osteotomía Sagital de Rama Mandibular/métodos , Dimensión del Dolor/métodos , Placebos , Náusea y Vómito Posoperatorios/etiología , Pregabalina/administración & dosificación , Estudios Prospectivos , Trometamina/uso terapéutico , Adulto JovenRESUMEN
PURPOSE: To evaluate quality of life (QoL) from a broad perspective by a comparison of Turkish patients undergoing orthognathic surgery to correct Angle Class III skeletal deformity with a control group composed of participants without dentofacial deformity using general health, generic oral health, and condition-specific QoL approaches. MATERIALS AND METHODS: Thirty patients who underwent orthognathic surgery to correct Class III relations (monomaxillary and bimaxillary groups) and 30 participants with Class I skeletal structure and good dentofacial harmony (control group) were evaluated. Condition-specific QoL through a 22-item Orthognathic Quality of Life Questionnaire (OQLQ), generic oral health-related QoL through a 14-item Short-Form Oral Health Impact Profile (OHIP-14), and generic health-related QoL through a 36-item Short-Form Health Survey (SF-36) were assessed. RESULTS: When the groups were compared, OQLQ scores showed a significant difference in the oral function domain only in the bimaxillary group (P < .05), and OHIP-14 scores showed significant differences in half the OHIP-14 subscale scores in the monomaxillary and bimaxillary groups (P < .05). The SF-36 scores showed significant differences only for the vitality domain in the monomaxillary group and the vitality and mental health domains in the bimaxillary group (P < .05). CONCLUSIONS: For condition-specific and health-related QoL, the QoL of orthognathic surgical patients appeared to be similar to that of participants without dentofacial deformities. Oral health-related QoL of orthognathic surgical patients seemed moderately similar to that of participants without dentofacial deformities. The combined use of these methods is helpful for evaluating QoL from a larger perspective.
Asunto(s)
Maloclusión de Angle Clase III/psicología , Procedimientos Quirúrgicos Ortognáticos/psicología , Calidad de Vida , Adolescente , Adulto , Femenino , Estudios de Seguimiento , Mentoplastia/psicología , Estado de Salud , Humanos , Masculino , Maloclusión de Angle Clase III/cirugía , Mandíbula/cirugía , Masticación/fisiología , Maxilar/cirugía , Salud Mental , Salud Bucal , Autoimagen , Adulto JovenRESUMEN
BACKGROUND: The periodontal status and distal bone level of the adjacent second molar can be negatively affected by the surgical extraction of an impacted lower third molar. Absorbable materials have some benefits, including enhancing primary wound coverage and promoting wound healing through isolation, clotting, wound stabilization and haemostasis. This study set out to compare primary and secondary healing and collagen-membrane-based primary healing after surgical removal of partially erupted impacted third molars (3Ms), evaluating the distal alveolar bone level (ABL) and periodontal status of the adjacent second molars (2Ms). METHODS: Patients who met the inclusion criteria were randomized into three groups: secondary healing (n = 28), primary healing (n = 27) and membrane-based primary healing (n = 29). Digital panoramic radiographs were obtained preoperatively (T1) and three months postoperatively (T2). The distances between the cemento-enamel junctions and the alveolar bone crests on the distal aspects of the adjacent 2Ms were measured using calibrated radiograph measurement software. The pocket depth and plaque index measurements were performed preoperatively and three months postoperatively. The periodontal plaque index (PPI) scores were registered on the distal aspects of the 2Ms, and the mean values were used. RESULTS: Three of the applied healing types positively affected periodontal pocket depth (PPD) and periodontal index values (p < 0.05). In terms of the ABL of the adjacent 2Ms, primary healing (p < 0.05) and membrane-based primary healing (p < 0.05) had superior results to secondary healing. CONCLUSION: Membrane use is promising for the distal bone gain and periodontal status of the adjacent 2M. TRIAL REGISTRATION: This clinical study was registered by the Australian New Zealand Clinical Trials Registry, with the trial number ACTRN12618001551280.